Biotectix Names New Vice President & General Manager
18-May-2010
Ann Arbor, Michigan - Biotectix, LLC announced today that James H. Arps, Ph.D. has joined the company as Vice President and General Manager. Dr. Arps brings more than 14 years of experience in the development and commercialization of advanced materials and coating technologies for medical device and related applications.
“Jim joins us at a key stage in Biotectix’s growth,” noted Marc Eichenberger, COO of Allied Minds, the parent company of Biotectix. “Jim’s experience working with leading medical device customers, strong technical background, and business acumen should serve us well as we advance the technology into additional preclinical trials with our co-development partners.”
Prior to his appointment at Biotectix, Dr. Arps held leadership positions at SurModics (NASDAQ:SRDX) as Director of Commercial Drug Delivery Technologies and a Senior Technical Advisor in Product Development. Previously, he directed the startup of the Surface Engineering Program at the Southwest Research Institute, a contract R&D and engineering services organization in San Antonio, TX. He completed his Doctorate in Materials Physics from Vanderbilt University and an M.S. in Management of Technology from the University of Texas.
“I am extremely excited about the opportunity with Biotectix, and look forward to working with the team to drive innovation and create effective partnerships with leading biomedical companies,” said Dr. Arps, “Biotectix’s proprietary conductive polymer technology offers unique benefits for the next generation of electrostimulation and sensing devices in the cardiac, neuro, and auditory fields and I look forward to seeing our work move to the next level in demonstrating clinical benefits.”
About Biotectix
Biotectix is developing a new class of conductive polymer materials and coatings for implantable devices and sensors that improve the safety, longevity, reliability, biological integration, and function of implantable biomedical devices. A number of benefits are driven by this platform technology without changing device size, shape, or implant procedure, including improved electrical performance , biocompatibility, and tissue response.
The technology addresses key limitations faced by the medical device industry including foreign body reactions, component stability, and long-term electrical performance in vivo. The materials are custom-designed for the specialized mechanical, electrical, and biological environments of the body, and provide an extremely high level of functional interfacing for medical electrodes.
Biotectix was formed by Allied Minds, a private equity company, based on technology originally developed at the University of Michigan, Ann Arbor. The founders and inventors continue to develop and validate the technology through research, collaborations, and partnerships with leading companies and research institutions.
About Allied Minds
Allied Minds is a U.S. capital investment firm with offices in Boston, Los Angeles, and Washington, DC. The Company creates spin out businesses based on early-stage technology developed at renowned U.S. Universities and National Labs and serves as a holding company that supports these businesses with capital, management, and shared services. Allied Minds is the premier firm to utilize this novel and fully integrated approach to technology investing. The Company’s subsidiary investments span multiple business sectors and offer an attractive risk-return profile, a deliverable timeline, and potential products that will be groundbreaking in their respective fields. These subsidiaries include AXI, BA Logix, Biotectix, Cephalogics, CryoXtract, GliaGen, Illumasonix, ProGDerm, Precision Biopsy, Purtein, RF Biocidics, SaltCheck, SiEnergy Systems, SoundCure and Spin Transfer Technologies. For more information please visit www.alliedminds.com.
For more information:
James Arps, Vice President & General Manager
Biotectix, an Allied Minds Company
jim.arps@biotectix.com
“Jim joins us at a key stage in Biotectix’s growth,” noted Marc Eichenberger, COO of Allied Minds, the parent company of Biotectix. “Jim’s experience working with leading medical device customers, strong technical background, and business acumen should serve us well as we advance the technology into additional preclinical trials with our co-development partners.”
Prior to his appointment at Biotectix, Dr. Arps held leadership positions at SurModics (NASDAQ:SRDX) as Director of Commercial Drug Delivery Technologies and a Senior Technical Advisor in Product Development. Previously, he directed the startup of the Surface Engineering Program at the Southwest Research Institute, a contract R&D and engineering services organization in San Antonio, TX. He completed his Doctorate in Materials Physics from Vanderbilt University and an M.S. in Management of Technology from the University of Texas.
“I am extremely excited about the opportunity with Biotectix, and look forward to working with the team to drive innovation and create effective partnerships with leading biomedical companies,” said Dr. Arps, “Biotectix’s proprietary conductive polymer technology offers unique benefits for the next generation of electrostimulation and sensing devices in the cardiac, neuro, and auditory fields and I look forward to seeing our work move to the next level in demonstrating clinical benefits.”
About Biotectix
Biotectix is developing a new class of conductive polymer materials and coatings for implantable devices and sensors that improve the safety, longevity, reliability, biological integration, and function of implantable biomedical devices. A number of benefits are driven by this platform technology without changing device size, shape, or implant procedure, including improved electrical performance , biocompatibility, and tissue response.
The technology addresses key limitations faced by the medical device industry including foreign body reactions, component stability, and long-term electrical performance in vivo. The materials are custom-designed for the specialized mechanical, electrical, and biological environments of the body, and provide an extremely high level of functional interfacing for medical electrodes.
Biotectix was formed by Allied Minds, a private equity company, based on technology originally developed at the University of Michigan, Ann Arbor. The founders and inventors continue to develop and validate the technology through research, collaborations, and partnerships with leading companies and research institutions.
About Allied Minds
Allied Minds is a U.S. capital investment firm with offices in Boston, Los Angeles, and Washington, DC. The Company creates spin out businesses based on early-stage technology developed at renowned U.S. Universities and National Labs and serves as a holding company that supports these businesses with capital, management, and shared services. Allied Minds is the premier firm to utilize this novel and fully integrated approach to technology investing. The Company’s subsidiary investments span multiple business sectors and offer an attractive risk-return profile, a deliverable timeline, and potential products that will be groundbreaking in their respective fields. These subsidiaries include AXI, BA Logix, Biotectix, Cephalogics, CryoXtract, GliaGen, Illumasonix, ProGDerm, Precision Biopsy, Purtein, RF Biocidics, SaltCheck, SiEnergy Systems, SoundCure and Spin Transfer Technologies. For more information please visit www.alliedminds.com.
For more information:
James Arps, Vice President & General Manager
Biotectix, an Allied Minds Company
jim.arps@biotectix.com
